Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. Eckhardt SG, et al. Among authors: hidalgo m. J Clin Oncol. 2000 Dec 15;18(24):4086-97. doi: 10.1200/JCO.2000.18.24.4086. J Clin Oncol. 2000. PMID: 11118470
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK. de Bono JS, et al. Among authors: hidalgo m. J Clin Oncol. 2002 Jan 1;20(1):96-109. doi: 10.1200/JCO.2002.20.1.96. J Clin Oncol. 2002. PMID: 11773159 Clinical Trial.
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG. Siu LL, et al. Among authors: hidalgo m. Clin Cancer Res. 2002 Jul;8(7):2157-66. Clin Cancer Res. 2002. PMID: 12114416 Clinical Trial.
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK. Patnaik A, et al. Among authors: hidalgo m. Clin Cancer Res. 2006 Dec 15;12(24):7406-13. doi: 10.1158/1078-0432.CCR-06-1886. Clin Cancer Res. 2006. PMID: 17189413 Clinical Trial.
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Rowinsky EK, et al. Among authors: hidalgo m. J Clin Oncol. 2000 Jan;18(1):178-86. doi: 10.1200/JCO.2000.18.1.178. J Clin Oncol. 2000. PMID: 10623708 Clinical Trial.
1,228 results